CompletedNot Applicable

Observational Study of Elizaria® in aHUS Patients

Russia50 participantsStarted 2019-12-19

Plain-language summary

It is a multicenter observational non-comparative study of the efficacy and safety of long-term pathogenetic Elizaria® therapy in patients with atypical Hemolytic Uremic Syndrome

Who can participate

Age range2 Months

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Written informed consent to study participation.
✓. Male and female patients aged 2 months and older with documented atypical hemolytic uremic syndrome (aHUS)diagnosis.

What they're measuring

Change in platelet count compared to the screening level

Timeframe: 52 week

Trial details

NCT IDNCT04749810

SponsorAO GENERIUM

Sponsor typeINDUSTRY

Study typeOBSERVATIONAL

Primary completion2022-02-28

View on ClinicalTrials.gov More Atypical Hemolytic Uremic Syndrome trials